Biotech financing is not dead. It’s different!

Apr 19, 2013

 May 22, 2013 ~ 7- 9 am ~ Hyatt Regency La Jolla~ 7am networking; 7:30am breakfast; 8am program
Registration closed Monday, May 20 11:00AM
Limited walk in registration is available for $60

Biotech financing has changed in the past few years.  Gone are the days of $50M start-ups, “platform” deals and fully integrated R&D organizations.  However, pre-revenue companies are going public, Big Pharma is doing deals, and companies are being formed.
We will explore topics such as:

  • Is the current public market real?  How long will it be open?
  • Should we confidentially submit under the JOBS act?
  • Should we consider an option deal as an alternative to another private round?
  • Just how does royalty financing work at an early stage company?

Join SDVG board member Nim Shah as moderator as we explore the new ways life science entrepreneurs are raising the funds they need to move their projects forward.
Our speakers are:
Eckard Weber, Partner, Domain Associates
Kleanthis G. Xanthopoulos, Ph.D., President & CEO, Regulus Therapeutics Inc.
Todd Davis, Managing Director, Healthcare Royalty Partners
Thank you to our sponsors!
BioMedVentures 2013